Literature DB >> 12819334

Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation.

Akira Hagiwara1, Yuichi Inoue, Kenichi Wakasa, Tomoko Haba, Takahiko Tashiro, Takeshi Miyamoto.   

Abstract

PURPOSE: To identify characteristic features of growth hormone (GH)-producing pituitary adenomas.
MATERIALS AND METHODS: A total of 174 pathologically proven pituitary adenomas were evaluated retrospectively on magnetic resonance (MR) images to determine the signal intensity (on T2-weighted images), maximum diameter, and amount of suprasellar and infrasellar extension. For microadenomas, sellar depth was also measured. GH-producing adenomas were classified at histologic evaluation as densely or sparsely granulated. Specimens from 38 adenomas were stained to assess the amounts of fibrous tissue, iron, and amyloid they contained. Results were correlated with the size and hormonal activity of adenomas by using the chi2, unpaired t, and Mann-Whitney U tests.
RESULTS: Among 174 pituitary adenomas, 42 were GH-producing adenomas. Of these, 16 were densely granulated, and 24 were sparsely granulated (two histologic specimens were lost). Signal intensity was evaluated among 153 adenomas. On T2-weighted MR images, hypointensity was seen more commonly in adenomas that produced GH (16 of 40 cases [40%]; P <.001) than in those that did not; hypointensity was nearly exclusive to densely granulated GH-producing adenomas. The amounts of amyloid, fibrous tissue, and iron contained in adenomas demonstrated little relationship with signal intensity. Average suprasellar extension was significantly smaller in adenomas that produced GH (-0.8 mm) than in those that did not (5.3 mm) (P <.001). GH-producing adenomas tended to demonstrate infrasellar extension rather than suprasellar extension. Average sellar depth associated with GH-producing microadenomas (13.3 mm) was significantly greater than for non-GH-producing microadenomas (9.7 mm; P <.001).
CONCLUSION: Characteristic features regarding growth direction and T2 signal intensity can be identified for GH-producing adenomas. Copyright RSNA, 2003.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819334     DOI: 10.1148/radiol.2282020695

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  42 in total

1.  MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2015-11-28       Impact factor: 3.633

Review 2.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

3.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 4.  T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.

Authors:  Iulia Potorac; Albert Beckers; Jean-François Bonneville
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging.

Authors:  Amit Mahajan; Richard A Bronen; Ali Y Mian; Sacit Bulent Omay; Dennis D Spencer; Silvio E Inzucchi
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

6.  Predictive role of dynamic contrast enhanced T1-weighted MR sequences in pre-surgical evaluation of macroadenomas consistency.

Authors:  Andrea Romano; Valeria Coppola; Mariangela Lombardi; Luigi Lavorato; Domenica Di Stefano; Emanuela Caroli; Maria Camilla Rossi Espagnet; Francesca Tavanti; Giuseppe Minniti; Giuseppe Trillò; Alessandro Bozzao
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

Review 7.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

8.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

9.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

10.  T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.

Authors:  M C Burlacu; D Maiter; T Duprez; E Delgrange
Journal:  Endocrine       Date:  2018-09-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.